- Home
- LCTX vs TARA Comparison
LCTX vs TARA Comparison
Compare LCTX & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- TARA
- Stock Information
- Founded
- LCTX 1990
- TARA N/A
- Country
- LCTX United States
- TARA United States
- Employees
- LCTX N/A
- TARA N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LCTX Health Care
- TARA Health Care
- Exchange
- LCTX Nasdaq
- TARA Nasdaq
- Market Cap
- LCTX 118.8M
- TARA 136.3M
- IPO Year
- LCTX N/A
- TARA N/A
- Fundamental
- Price
- LCTX $0.41
- TARA $4.10
- Analyst Decision
- LCTX Strong Buy
- TARA Strong Buy
- Analyst Count
- LCTX 5
- TARA 4
- Target Price
- LCTX $4.20
- TARA $22.67
- AVG Volume (30 Days)
- LCTX 1.8M
- TARA 225.7K
- Earning Date
- LCTX 03-10-2025
- TARA 03-05-2025
- Dividend Yield
- LCTX N/A
- TARA N/A
- EPS Growth
- LCTX N/A
- TARA N/A
- EPS
- LCTX N/A
- TARA N/A
- Revenue
- LCTX $9,499,000.00
- TARA N/A
- Revenue This Year
- LCTX $25.10
- TARA N/A
- Revenue Next Year
- LCTX $35.67
- TARA N/A
- P/E Ratio
- LCTX N/A
- TARA N/A
- Revenue Growth
- LCTX 6.19
- TARA N/A
- 52 Week Low
- LCTX $0.40
- TARA $1.60
- 52 Week High
- LCTX $1.56
- TARA $10.48
- Technical
- Relative Strength Index (RSI)
- LCTX 30.50
- TARA 44.52
- Support Level
- LCTX $0.47
- TARA $4.41
- Resistance Level
- LCTX $0.55
- TARA $4.63
- Average True Range (ATR)
- LCTX 0.04
- TARA 0.27
- MACD
- LCTX -0.00
- TARA -0.01
- Stochastic Oscillator
- LCTX 4.04
- TARA 14.13
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops, and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).